Current report 21/2022 – Admission and introduction of 5,000 ordinary C-series bearer shares of the Company to stock exchange trading

Current report No. 21/2022

Date prepared: 15/07/2022

Abbreviated name of the issuer: CELON PHARMA S.A.

Subject: Admission and introduction of 5,000 ordinary C-series bearer shares of the Company to stock exchange trading

Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information

Content of the report:

The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on July 15, 2022 the Management Board of the Warsaw Stock Exchange (“WSE”) has adopted a resolution concerning the admission and introduction of the Company’s ordinary C-series bearer shares to stock exchange trading on the GPW Main Market List.

In its resolution, the Warsaw Stock Exchange Management Board stated that pursuant to § 19.1 and § 19.2 of the WSE Rules, 5,000 ordinary C-series bearer shares of the Company, having the nominal value of PLN 0.10 each, designated with the “PLCLNPH00015” code by the Central Securities Depository of Poland, are admitted to stock exchange trading on the primary market.

The GPW Management Board decided to introduce the above-mentioned shares of the Company to trading on the primary market as of July 22, 2022, subject to the assimilation of these shares with the shares in the exchange trade, designated with the “PLCLNPH00015” code, by the Central Securities Depository of Poland on July 22, 2022.